It is one of the more direct questions a patient can ask after receiving a sleep apnea diagnosis — and it deserves a direct answer. How long can someone live with untreated sleep apnea is not a simple question to answer with a single number, because the answer depends heavily on severity, age, the presence of other health conditions, and individual biology. But the research is substantial enough to say clearly: untreated sleep apnea shortens life expectancy, and the more severe it is, the greater the risk.
What the Mortality Data Shows
Several large studies have examined all-cause mortality in patients with untreated obstructive sleep apnea compared to matched controls without the condition. The findings are consistent. Patients with moderate to severe untreated sleep apnea have significantly higher mortality rates than those without sleep apnea, with some studies finding the risk of death from any cause to be two to three times higher over follow-up periods of several years.
A landmark study following over 1,500 patients for up to 18 years found that severe untreated sleep apnea — defined as an AHI of 30 or more — was associated with a nearly three-fold increase in cardiovascular mortality compared to those without sleep apnea. Patients who used CPAP consistently had mortality rates comparable to those without sleep apnea, suggesting that the elevated risk is substantially driven by the untreated condition rather than by factors inherent to the patient population.
It is important to note that these are population-level statistics. They describe risk across large groups of people and cannot predict what will happen to any specific individual. Someone with severe untreated sleep apnea may live for decades without a catastrophic event. Someone with mild apnea may have an early cardiac event influenced by other risk factors. What the data establishes is that untreated sleep apnea meaningfully shifts the odds in the wrong direction.
The Health Conditions That Drive Early Mortality
Sleep apnea does not typically kill directly. What it does is accelerate or worsen a set of serious health conditions that are themselves major causes of death.
Cardiovascular disease is the most significant. Untreated sleep apnea causes repeated drops in blood oxygen, spikes in blood pressure, and surges in sympathetic nervous system activity throughout the night. Over months and years, this puts substantial stress on the heart and blood vessels. The result is an elevated risk of hypertension, coronary artery disease, heart failure, and arrhythmias — particularly atrial fibrillation, which is itself a major stroke risk factor. Cardiovascular disease is the leading cause of death in patients with untreated severe sleep apnea.
Stroke risk is independently elevated in sleep apnea patients beyond what is explained by hypertension alone. The combination of nocturnal hypoxia, blood pressure surges, and the prothrombotic effects of chronic sleep fragmentation creates conditions favorable to both ischemic and hemorrhagic stroke.
Type 2 diabetes is both a risk factor for and a consequence of untreated sleep apnea. Chronic intermittent hypoxia and sleep fragmentation impair insulin sensitivity and glucose regulation. Patients with untreated sleep apnea have higher rates of developing type 2 diabetes, and those who already have diabetes experience worse glycemic control. Diabetes in turn accelerates cardiovascular disease, creating a compounding risk profile.
Cognitive decline has emerged as an increasingly documented consequence of long-term untreated sleep apnea, with growing evidence linking chronic nocturnal hypoxia and disrupted glymphatic clearance to earlier onset of mild cognitive impairment and dementia. While dementia itself is not typically classified as a direct cause of death, it significantly affects quality of life, independence, and vulnerability to other fatal conditions.
Does Severity Determine How Much Risk You Carry?
Yes, substantially. The mortality data consistently shows a dose-response relationship — the higher the AHI, the greater the associated risk. Mild sleep apnea, defined as an AHI between 5 and 14, carries a lower excess mortality risk than moderate or severe apnea, though it is not without consequence, particularly in patients who also have cardiovascular disease or other comorbidities.
Severe sleep apnea — an AHI of 30 or above — carries the most clearly documented mortality risk. At this level, patients are experiencing 30 or more breathing disruptions per hour, often accompanied by significant oxygen desaturations that stress the cardiovascular system repeatedly throughout every night of sleep.
Age also modifies the risk. Some research has found that the mortality association between sleep apnea and cardiovascular death is strongest in middle-aged adults and somewhat attenuated in the very elderly, possibly because survival bias affects the older patient population — those most vulnerable may not have survived to older age in the study cohorts.
What Treatment Changes About the Prognosis
The evidence that treating sleep apnea reduces mortality risk is consistent across multiple studies, though randomized controlled trial data is more limited than observational data. What is clear is that consistent CPAP users show cardiovascular event rates and mortality rates that are substantially lower than untreated patients with equivalent AHI scores — and in many studies, comparable to people without sleep apnea at all.
This matters for answering the original question. The life expectancy gap between someone with severe sleep apnea and someone without it is substantially narrowed by effective treatment. Untreated sleep apnea is what drives the elevated risk, not sleep apnea as a biological state in itself.
The Honest Answer
There is no precise number of years that can be attached to untreated sleep apnea as a universal answer. What the research supports is this: moderate to severe untreated sleep apnea meaningfully increases the risk of cardiovascular death, stroke, and other serious health consequences, and does so in a way that compounds over time. The longer it goes untreated and the more severe it is, the greater the cumulative damage to the cardiovascular system and other organ systems.
For patients weighing whether to pursue treatment, that framing is more useful than a single statistic. The risk is real, it is well documented, and in the majority of cases it is modifiable with treatment that is available, covered by insurance, and for most patients manageable with some persistence through the adjustment period.